Project Grant R21AG087594
Award Date
5/1/24
Completion Date
4/30/26
Dollars Obligated
$432K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $431,750 to a partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support the development and evaluation of a novel immuno-gene therapy targeting oligomeric tau, a key driver of neurodegeneration in tauopathies like Alzheimer's disease. Specifically, the project aims to engineer a single-chain antibody fragment (scFv) derived from the anti-tau...
This $574,474 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development and preclinical testing of self-adjuvanting peptide nanofiber (PNF) vaccines targeting amyloid-beta (Aβ) and tau proteins for the treatment of Alzheimer's disease (AD) and frontotemporal dementia (FTD). The Washington University in St. Louis, the prime awardee, will lead this effort in collaboration with the University of Texas Medical Branch at Galveston as a...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), provides $499,911 to Aeton Therapeutics Inc. to develop an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: 1) evaluate the effectiveness of Aeton's lead candidate AT-01 in treating neural cells and organoids, compared to another anti-tau antibody, and 2) determine the efficacy and safety of AT-01 versus the comparator in...
This Project Grant award from the National Institute on Aging (under CFDA 93.866 - Aging Research) provides $496,373.00 to Jillion Therapeutics Inc. to identify small molecule compounds that can bind to and modify the biological activity of tau protein monomers and oligomers. The goal is to develop potential therapies for Alzheimer's disease and other tauopathy neurodegenerative disorders. The key products to be delivered include:
Completion of a DNA-encoded library (DEL) screening campaign...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Notre Dame du Lac is funding a 5-year, $553,998 research project to develop conformationally constrained peptide macrocycles, termed "mini-Taus", that mimic the structure and function of pathological tau protein filaments associated with neurodegenerative tauopathies.
The key objectives are to: 1) synthesize a diverse library of macrocyclic peptides designed to adopt...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $652,575 provides funding to New York University School of Medicine to conduct research on the disruption of endosomal microautophagy (EMI) by pathological tau protein in Alzheimer's disease (AD). The key objectives are to 1) elucidate the role of pathological tau in destabilizing the EMI pathway, 2) identify which EMI components are most vulnerable to tau pathology, and 3)...
The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration....
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD).
The project aims to develop new...
The University of North Carolina at Chapel Hill (UNC-CH) received a $424,095 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop a CRISPR/Cas13 gene therapy targeting the tau protein for the treatment of Alzheimer's disease and other tauopathies. The project aims to identify and validate optimal guide RNAs to deplete specific tau isoforms in neurons, and evaluate the therapeutic potential of this approach in preclinical Alzheimer's disease mouse...